PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

基本信息

批准号：
6489030
负责人：
FAITH H KUNG
金额：
$ 4.39万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1980
资助国家：
美国
起止时间：
1980-07-01 至 2002-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6489030
关键词：
6 thiopurine Ewing's tumor Hodgkin's disease Wilms' tumor XomaZyme acivicin acute leukemia acute lymphocytic leukemia acute myelogenous leukemia adolescence (12-20) antineoplastics asparaginase astrocytoma biological response modifiers bone marrow transplantation brain neoplasms cancer registry /resource cancer risk central nervous system neoplasms child (0-11) chronic myelogenous leukemia cis platinum compound clinical research clinical trial phase I colony stimulating factor combination cancer therapy combination chemotherapy cooperative study cyclophosphamide cyclosporines cytosine arabinoside daunorubicin deferoxamine deoxycoformycin doxorubicin drug screening /evaluation enalapril ependymoma etoposide fazarabine fluorouracil germ cell neoplasms glioma hepatoblastoma hepatocellular carcinoma human genetic material tag human immunodeficiency virus 1 human subject human therapy evaluation human tissue ifosfamide interferons interleukin 2 medulloblastoma melphalan metastasis methotrexate mitoxantrone molecular oncology neoplasm /cancer chemotherapy neoplasm /cancer classification /staging neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunology neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer relapse /recurrence neoplasm /cancer surgery neuroblastoma nonHodgkin's lymphoma osteosarcoma paclitaxel pediatric pharmacology podophyllin prednisone retinoate rhabdomyosarcoma tissue resource /registry topotecan trimetrexate vincristine

项目摘要

This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities.

该提案代表了支持继续参与的请求儿科肿瘤学组 (POG)。此次合作研究致力于化学治疗、免疫学和分子学研究治疗急性白血病和其他疾病的生物学方法儿童肿瘤性疾病。显着的无病生存率在临床药理学方面取得了成就和贡献，肿瘤免疫学和癌症生物学。然而真正的目的是这些研究是通过治疗来根除肿瘤性疾病。正在设计研究以反映攻击强度的增加在肿瘤细胞上。合作小组技术允许迅速对一系列合理规模的有希望的线索进行评估化疗。这些线索或新方法通常是由该小组自己在临床肿瘤学方面的工作成果。这样，就完成了一个协议经常建议在新协议中探索新的途径。波格领导急性淋巴细胞免疫表型研究白血病、NTX 聚谷氨酸盐在白血病细胞中的积累以及 N-myc 神经母细胞瘤中的基因扩增，将结果与患者相关联结果，然后将其纳入设计的新治疗方案中提高癌症儿童的生存率。分部加州大学圣地亚哥分校儿科血液学/肿瘤学拥有24年合作经验（10年在CALGB，14年在POG）临床试验。过去5年4个联合体成员机构已纳入 332 名接受治疗和非治疗的患者治疗研究和卫星，211 名患者。我们的调查员曾在 12 个委员会任职，设计/协调 16 项团体方案研究。我们还为 15 份团体出版物/演示文稿做出了贡献。我们的研究人员将继续设计和主持治疗方案，并且在委员会任职。于博士实验室将继续探索新的供团体使用的免疫治疗药物，并作为团体参考实验室。我们计划继续积极参与各个阶段 POG 活动。

项目成果

期刊论文数量（10）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.

脱氧考福霉素治疗第二次缓解早期儿童 T 细胞急性淋巴细胞白血病：一项儿科肿瘤学小组研究。

DOI：
10.1002/mpo.2950160507
发表时间：
1988
期刊：
Medical and pediatric oncology
影响因子：
0
作者：
Winick,N;Buchanan,GR;Murphy,SB;Yu,A;Boyett,J
通讯作者：
Boyett,J

Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

依托泊苷（VP-16）治疗儿童复发性恶性实体瘤的临床试验。

DOI：
10.1007/bf00170776
发表时间：
1988
期刊：
Investigational new drugs
影响因子：
3.4
作者：
Kung,F;Hayes,FA;Krischer,J;MahoneyJr,D;Leventhal,B;Brodeur,G;Berry,DH;Dubowy,R;Toledano,S
通讯作者：
Toledano,S

Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139).

脑干肿瘤中的超分割照射和同步顺铂：一项儿科肿瘤学小组试点研究 (9139)。

DOI：
10.1159/000120794
发表时间：
1994
期刊：
Pediatric neurosurgery
影响因子：
0.7
作者：
Kadota,RP;Mandell,LR;Fontanesi,J;Kovnar,EH;Krischer,J;Kun,LE;Friedman,HS
通讯作者：
Friedman,HS

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.

使用丙氨酸作为甲硫腺苷磷酸化酶选择性疗法在体外治疗 T 细胞急性淋巴细胞白血病。

DOI：
发表时间：
1999
期刊：
Cancer research.
影响因子：
0
作者：
Batova,A;Diccianni,MB;Omura-Minamisawa,M;Yu,J;Carrera,CJ;Bridgeman,LJ;Kung,FH;Pullen,J;Amylon,MD;Yu,AL
通讯作者：
Yu,AL

Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.

在儿科癌症患者中进行的 I 期试验中抗神经节苷脂 GD2 mAb 14G2a 的药代动力学。